Trials / Completed
CompletedNCT06214481
A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants
A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rocatinlimab (AMG 451) Administered Subcutaneously in Healthy Chinese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to evaluate the pharmacokinetics of rocatinlimab after single subcutaneous (SC) administration in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rocatinlimab | Administered SC. |
Timeline
- Start date
- 2024-01-23
- Primary completion
- 2024-05-27
- Completion
- 2024-06-05
- First posted
- 2024-01-19
- Last updated
- 2026-01-07
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06214481. Inclusion in this directory is not an endorsement.